PREVALENCE OF CLAUDIN18.2 AND PD-L1 EXPRESSION IN CHINESE GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

被引：1
|
作者：
Mao, Linlin [1 ]
Yi, Wei [1 ]
Lin, Xu-Alan [1 ]
Gu, Ying [1 ]
Xia, Zhenzhong [1 ]
Qi, Chuan [1 ]
Shi, Michael [1 ]
Yu, Steven [1 ]
Qian, Xueming [1 ]
机构：
[1] Suzhou Transcenta Therapeut Co Ltd, Suzhou, Peoples R China
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷
关键词：
D O I：
10.1136/jitc-2022-SITC2022.0105
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
105
引用
收藏
页码：A115 / A115
页数：1
相关论文
共 50 条
  • [1] Impact of HER2 and PD-L1 co-expression in Claudin18.2 positive resectable gastroesophageal cancers
    Cammarota, A.
    Devonshire, G.
    Miremadi, A.
    Ustaoglu, A.
    Filippi, B.
    Zhuang, J. L.
    Zamani, S.
    Masque-Soler, N.
    Rimassa, L.
    Fitzgerald, R. C.
    Smyth, E.
    ANNALS OF ONCOLOGY, 2023, 34 : S877 - S878
  • [2] Claudin 18.2 (CLDN18.2) expression prevalence, prognostication and clinical variables in gastric and gastroesophageal junction adenocarcinoma patient samples
    Sewastjanow, Matheus
    Yamashita, Kohei
    Iwata, Kenneth K.
    Moran, Diarmuid
    Elsouda, Dina
    Pizzi, Melissa
    Vicentini, Ernesto Rosa
    Shanbhag, Namita
    Ta, Anh
    Waters, Rebecca
    Chatterjee, Deyali
    Ajani, Jaffer
    CANCER RESEARCH, 2023, 83 (07)
  • [3] Claudin18.2 expression in pulmonary mucinous adenocarcinoma
    Yuming Wang
    Yike Gao
    Zhiwen Zhang
    Zixin Zhang
    Anqi Wang
    Kun Zhao
    Miao Zhang
    Sumei Zhang
    Mei Li
    Jian Sun
    Dan Guo
    Zhiyong Liang
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 12923 - 12929
  • [4] Claudin18.2 expression in pulmonary mucinous adenocarcinoma
    Wang, Yuming
    Gao, Yike
    Zhang, Zhiwen
    Zhang, Zixin
    Wang, Anqi
    Zhao, Kun
    Zhang, Miao
    Zhang, Sumei
    Li, Mei
    Sun, Jian
    Guo, Dan
    Liang, Zhiyong
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (14) : 12923 - 12929
  • [5] Better performance of pan-claudin18 antibodies on claudin18.2 detection in gastric adenocarcinoma than claudin18.2 specific antibody
    Ni, S.
    Sheng, W.
    Su, W.
    Lu, H.
    Yan, Q.
    Xu, J.
    Hua, C.
    Huang, Z.
    Ruan, L.
    Zhu, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S244 - S245
  • [6] The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma
    Brar, Gagandeep
    Shah, Manish A.
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2019, 12
  • [7] Clinical Implications of Claudin18.2 Expression in Patients With Gastric Cancer
    Baek, Jin Ho
    Park, Dong Jin
    Kim, Gyu Yeol
    Cheon, Jaekyung
    Kang, Byung Woog
    Cha, Hee Jeong
    Kim, Jong Gwang
    ANTICANCER RESEARCH, 2019, 39 (12) : 6973 - 6979
  • [8] Correlation of Claudin18.2 expression with clinicopathological characteristics and prognosis in gastric cancer
    Tao, Daoyu
    Guan, Bingxin
    Li, Zengxian
    Jiao, Meng
    Zhou, Chengjun
    Li, Hui
    PATHOLOGY RESEARCH AND PRACTICE, 2023, 248
  • [9] Prevalence of claudin 18.2 expression in gastric/gastroesophageal junction adenocarcinoma among patients in TranStar101 and TranStar102 clinical trials
    Shen, Li
    Mao, Carol
    Lin, Alan
    Gu, Ying
    Milata, Jenny
    Zhang, Lijuan
    Qi, Chuan
    Yao, Jenny
    Yu, Steven
    Yue, Changjun
    Shen, Lin
    Janjigian, Yelena
    Qian, Xueming
    Chang, Wen-I
    Germa, Caroline
    CANCER RESEARCH, 2024, 84 (06)
  • [10] The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma
    Zhihao Lu
    Silu Yang
    Xuerui Luo
    Yang Shi
    Jong-Seok Lee
    Sanjeev Deva
    Tianshu Liu
    Yee Chao
    Yun Zhang
    Ruiqi Huang
    Yaling Xu
    Zhirong Shen
    Lin Shen
    Gastric Cancer, 2022, 25 : 943 - 955
12345